Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (38)

2024

  1. Prognostic Value of D-dimer to Lymphocyte Ratio (DLR) in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Validation Study in a National Cohort

    Viruses, Vol. 16, Núm. 3

2023

  1. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry

    Scientific Reports, Vol. 13, Núm. 1

  2. Patients with COPD hospitalized due to COVID-19 in Spain: a comparison between the first and second wave

    Revista Clinica Espanola, Vol. 223, Núm. 5, pp. 298-309

2022

  1. Coronavirus disease 2019 hospitalization outcomes in persons with and without HIV in Spain

    AIDS, Vol. 36, Núm. 5, pp. 683-690

  2. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 761-775

  3. The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers

    Journal of General Internal Medicine, Vol. 37, Núm. 1, pp. 168-175

  4. Use of glucocorticoids megadoses in SARSCoV- 2 infection in a spanish registry: SEMICOVID- 19

    PLoS ONE, Vol. 17, Núm. 1 January

  5. WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales

    Journal of General Internal Medicine, Vol. 37, Núm. 8, pp. 1980-1987

2021

  1. Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  2. Gender-based differences by age range in patients hospitalized with covid-19: A spanish observational cohort study

    Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-21

  3. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy

    BMC Infectious Diseases, Vol. 21, Núm. 1

  4. Predicting critical illness on initial diagnosis of COVID-19 based on easily obtained clinical variables: development and validation of the PRIORITY model

    Clinical Microbiology and Infection, Vol. 27, Núm. 12, pp. 1838-1844

2020

  1. Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias

    Clinica e Investigacion en Arteriosclerosis, Vol. 32, Núm. 5, pp. 209-218

2019

  1. Non-HDL cholesterol as a therapeutic goal

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 28-33

  2. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects

    Clinica e Investigacion en Arteriosclerosis

  3. Standards for global cardiovascular risk management arteriosclerosis

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 1-43

2018

  1. Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration

    Clinica e Investigacion en Arteriosclerosis, Vol. 30, Núm. 4, pp. 188-192

2017

  1. Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study

    American Journal of Cardiovascular Drugs, Vol. 17, Núm. 2, pp. 135-142

  2. Enfermedad renal crónica y dislipidemia

    Clinica e Investigacion en Arteriosclerosis

  3. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease

    Clinica e Investigacion en Arteriosclerosis